BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 2323651)

  • 1. Effective prevention of central nervous system leukemia with intrathecal methotrexate and intrathecal methotrexate, cytosine arabinoside, and hydrocortisone in childhood acute lymphocytic leukemia.
    Aur RJ; Hanna M; Sabbah R; Sackey K; Willoughby S; Atwood J
    Haematol Blood Transfus; 1990; 33():504-10. PubMed ID: 2323651
    [No Abstract]   [Full Text] [Related]  

  • 2. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica.
    Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi AM; Messina C; Mori PG; Miniero R; Colella R; Basso G
    J Clin Oncol; 1995 Oct; 13(10):2497-502. PubMed ID: 7595699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of two regimens for high-risk acute lymphocytic leukemia in childhood. A Pediatric Oncology Group Study.
    van Eys J; Berry D; Crist W; Doering E; Fernbach D; Pullen J; Shuster J; Wharam M
    Cancer; 1989 Jan; 63(1):23-9. PubMed ID: 2910421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group.
    Matloub Y; Lindemulder S; Gaynon PS; Sather H; La M; Broxson E; Yanofsky R; Hutchinson R; Heerema NA; Nachman J; Blake M; Wells LM; Sorrell AD; Masterson M; Kelleher JF; Stork LC;
    Blood; 2006 Aug; 108(4):1165-73. PubMed ID: 16609069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BFM group treatment results in relapsed childhood acute lymphoblastic leukemia.
    Henze G; Fengler R; Hartmann R; Niethammer D; Schellong G; Riehm H
    Haematol Blood Transfus; 1990; 33():619-26. PubMed ID: 2182452
    [No Abstract]   [Full Text] [Related]  

  • 6. Intermittent low-dose central nervous system radiation for high-risk pediatric leukemia patients: preliminary results.
    Belasco JB; Rate W; Mancini A; Paolucci G; Frezza G; Rosito P; Vecchi V; D'Angio GJ
    Med Pediatr Oncol; 1991; 19(2):106-9. PubMed ID: 2011094
    [No Abstract]   [Full Text] [Related]  

  • 7. Spinal Cord Toxicity from Intrathecal Chemotherapy: A Case with Clinicopathologic Correlation.
    Dornbos D; Elder JB; Otero JJ; Baiocchi RA; Slone HW; Puduvalli VK; Giglio P
    World Neurosurg; 2019 Aug; 128():381-384. PubMed ID: 31128312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different patterns of relapse associated with three intensive treatment regimens for pediatric E-rosette positive T-cell leukemia: a Pediatric Oncology Group study.
    Falletta JM; Shuster JJ; Crist WM; Pullen DJ; Borowitz MJ; Wharam M; Patterson R; Foreman E; Vietti TJ
    Leukemia; 1992 Jun; 6(6):541-6. PubMed ID: 1602793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia.
    Pui CH; Mahmoud HH; Rivera GK; Hancock ML; Sandlund JT; Behm FG; Head DR; Relling MV; Ribeiro RC; Rubnitz JE; Kun LE; Evans WE
    Blood; 1998 Jul; 92(2):411-5. PubMed ID: 9657739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensive alternating drug pairs for treatment of high-risk childhood acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.
    Lauer SJ; Camitta BM; Leventhal BG; Mahoney DH; Shuster JJ; Adair S; Casper JT; Civin CI; Graham M; Kiefer G
    Cancer; 1993 May; 71(9):2854-61. PubMed ID: 8467463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction in central nervous system leukemia with a pharmacokinetically derived intrathecal methotrexate dosage regimen.
    Bleyer WA; Coccia PF; Sather HN; Level C; Lukens J; Niebrugge DJ; Siegel S; Littman PS; Leikin SL; Miller DR
    J Clin Oncol; 1983 May; 1(5):317-25. PubMed ID: 6366138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolated central nervous system relapse in acute lymphocytic leukemia (ALL) in children. Experiences of the Swiss Pediatric Oncology Group (SPOG/SAKK) 1976-1986.
    Stucki F; Arnet B; Baumgartner C; Beck D; Berchtold W; Bertrand AM; Bleher EA; Caflisch U; Delaleu B; Feldges A
    Helv Paediatr Acta; 1988 Nov; 43(3):187-93. PubMed ID: 3065299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective preventive central nervous system therapy with extended triple intrathecal therapy and the modified ALL-BFM 86 chemotherapy program in an enlarged non-high risk group of children and adolescents with non-B-cell acute lymphoblastic leukemia: the Israel National Study report.
    Stark B; Sharon R; Rechavi G; Attias D; Ballin A; Cividalli G; Burstein Y; Sthoeger D; Abramov A; Zaizov R
    Cancer; 2000 Jan; 88(1):205-16. PubMed ID: 10618625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuropsychological outcomes from a randomized trial of triple intrathecal chemotherapy compared with 18 Gy cranial radiation as CNS treatment in acute lymphoblastic leukemia: findings from Dana-Farber Cancer Institute ALL Consortium Protocol 95-01.
    Waber DP; Turek J; Catania L; Stevenson K; Robaey P; Romero I; Adams H; Alyman C; Jandet-Brunet C; Neuberg DS; Sallan SE; Silverman LB
    J Clin Oncol; 2007 Nov; 25(31):4914-21. PubMed ID: 17971588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parenchymal brain leukemia. Case report: problems related to the diagnosis and treatment.
    Corbetta A; Jankovic M; Conter V; Fuga T; Crivellaro M; Masera G
    Haematologica; 1991; 76(4):324-6. PubMed ID: 1794739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ascending myelopathy after chemotherapy for central nervous system acute lymphoblastic leukemia: correlation with cerebrospinal fluid myelin basic protein.
    Bates SE; Raphaelson MI; Price RA; McKeever P; Cohen S; Poplack DG
    Med Pediatr Oncol; 1985; 13(1):4-8. PubMed ID: 2578602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensive alternating drug pairs after remission induction for treatment of infants with acute lymphoblastic leukemia: A Pediatric Oncology Group Pilot Study.
    Lauer SJ; Camitta BM; Leventhal BG; Mahoney D; Shuster JJ; Kiefer G; Pullen J; Steuber CP; Carroll AJ; Kamen B
    J Pediatr Hematol Oncol; 1998; 20(3):229-33. PubMed ID: 9628434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiagent chemotherapy in relapsed acute lymphoblastic leukemia in children.
    Belasco JB; Luery N; Scher C
    Cancer; 1990 Dec; 66(12):2492-7. PubMed ID: 2249189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Teniposide (VM-26) and continuous infusion cytosine arabinoside for initial induction failure in childhood acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.
    Ochs J; Rivera GK; Pollock BH; Buchanan G; Crist W; Freeman AI
    Cancer; 1990 Oct; 66(8):1671-7. PubMed ID: 2208021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple intrathecal therapy without cranial irradiation for central nervous system preventive therapy in childhood acute lymphoblastic leukemia.
    Lin WY; Liu HC; Yeh TC; Wang LY; Liang DC
    Pediatr Blood Cancer; 2008 Mar; 50(3):523-7. PubMed ID: 17455314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.